Posted by Michael Wonder on 18 Jan 2021
ICER issues correction to final evidence report on new therapies for bladder cancer
15 January 2021 - After correcting an input to the cost-effectiveness model, ICER’s health-benchmark price benchmark range for nadofaragene firadenovec has been updated to $158,600-$262,000.
The Institute for Clinical and Economic Review today issued a revised Final Evidence Report that corrects a data entry error within the cost-effectiveness analysis of nadofaragene firadenovec (Adstiladrin, FKD Therapies Oy and FerGene) for the treatment of non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin intravesical therapy.
ICER’s health benefit price benchmark range for nadofaragene firadenovec has been revised accordingly and is now $158,600-$262,000. The original version of this report, published on December 17, 2020, inaccurately stated that this range was $121,000-$201,000.
